Exact Mass: 375.17353860000003
Exact Mass Matches: 375.17353860000003
Found 500 metabolites which its exact mass value is equals to given mass value 375.17353860000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Haloperidol
A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279) CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7649; ORIGINAL_PRECURSOR_SCAN_NO 7647 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7684; ORIGINAL_PRECURSOR_SCAN_NO 7682 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7681; ORIGINAL_PRECURSOR_SCAN_NO 7680 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7678; ORIGINAL_PRECURSOR_SCAN_NO 7677 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7604; ORIGINAL_PRECURSOR_SCAN_NO 7602 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7639; ORIGINAL_PRECURSOR_SCAN_NO 7638 D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics CONFIDENCE standard compound; EAWAG_UCHEM_ID 3566 CONFIDENCE standard compound; INTERNAL_ID 1122 Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
Gatifloxacin
C19H22FN3O4 (375.15942640000003)
Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. [Wikipedia] J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D019999 - Pharmaceutical Solutions > D009883 - Ophthalmic Solutions D004791 - Enzyme Inhibitors
Cyphenothrin
C24H25NO3 (375.18343400000003)
D010575 - Pesticides > D007306 - Insecticides > D011722 - Pyrethrins Same as: D01511
2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)-
Simmondsin
Simmondsin is found in coffee and coffee products. Simmondsin is a constituent of Simmondsia chinensis (jojoba) Simmondsin is an extract of jojoba seeds (pronounced "ho-HO-bah") (Simmondsia chinensis), it was traditionally thought to be a toxic substance due to jojoba seed meal causing weight loss in animals, but recently it has been researched as a potential treatment for reducing appetite of obese individuals by helping to reduce craving for food. Several mechanisms of action are thought to be involved in the appetite suppressant effect
(E)-1-[(2R)-2-(2-Hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one
Linifanib
C21H18FN5O (375.14953099999997)
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
N-[4-(3-Amino-1h-indazol-4-yl)phenyl]-n1-(2-fluoro-5-methylphenyl) urea
C21H18FN5O (375.14953099999997)
Theodrenaline
C17H21N5O5 (375.15426160000004)
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Afn-1252
Seneciphyllinine
Acetylseneciphylline is a pyrrolizine alkaloid that is seneciphylline in which the hydroxy hydrogen has been replaced by an acetyl group. It has a role as a Jacobaea metabolite. It is a macrocyclic lactone, an olefinic compound, an organic heterotricyclic compound, a pyrrolizine alkaloid and an acetate ester. It is functionally related to a seneciphylline. CID 15120074 is a natural product found in Senecio rodriguezii and Senecio pterophorus with data available. A pyrrolizine alkaloid that is seneciphylline in which the hydroxy hydrogen has been replaced by an acetyl group.
[(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-[(E)-3-(4-hydroxy-3-methoxyphenyl)propenoyloxy]-1aβ-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside
1,3-diethyl 2-{[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl)amino]methylidene}propanedioate
C16H20F3N3O4 (375.14058360000007)
4-(4,6-dimethyl-9-oxo-4,9-dihydro-1H-imidazo[1,2-a]pyrrolo[3,2-d]pyrimidin-7-yl)-2-methoxycarbonylamino-butyric acid methyl ester
C17H21N5O5 (375.15426160000004)
9-O-(threo-2-hydroxy-2-methyl-3-phenylacetoxy-butyryl)-(-)-trachelanthamidine|minalobine R
C21H29NO5 (375.20456240000004)
9-(1-hydroxyhexyl)-3-(2-hydroxypropyl)-6a-methyl-9,9a-dihydrofuro[2,3-h]isoquinoline-6,8(2h,6ah)-dione
C21H29NO5 (375.20456240000004)
erythro-1-[1-oxo-9(3,4-methylenedioxyphenyl)-8,9-dihydroxy-2E-nonenyl]-piperidine|threo-1-[1-oxo-9(3,4-methylenedioxyphenyl)-8,9-dihydroxy-2E-nonenyl]-piperidine
C21H29NO5 (375.20456240000004)
(13bS)-4-acetyl-8,13,13b,14-tetrahydro-1-(1-hydroxyethyl)indolo[2,3:3,4]pyrido[1,2-b] [2,7]naphthyridin-5(7H)-one|Latifoliamide E
N-[2-(4-Hydroxyphenyl)ethyl]-3-(ethylthio)-3-(4-hydroxy-3-methoxyphenyl)propanamide
C20H25NO4S (375.15042100000005)
2alpha-hydroxy-comosivine|2alpha-Hydroxycomosivine
C21H29NO5 (375.20456240000004)
10,16-dioxo-16,19-seco-strychnidine-19-carbonitrile|N-Cyano-sec-pseudostrychnin|N-Cyano-sec-pseudostrychnine
Linifanib
C21H18FN5O (375.14953099999997)
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
bisIMI
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
Gatifloxacin
C19H22FN3O4 (375.15942640000003)
A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D019999 - Pharmaceutical Solutions > D009883 - Ophthalmic Solutions D004791 - Enzyme Inhibitors
haloperidol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
Ala Ala Asn Thr
Ala Ala Gln Ser
Ala Ala Ser Gln
Ala Ala Thr Asn
Ala Asp Gly Asn
Ala Asp Asn Gly
Ala Gly Asp Asn
Ala Gly Asn Asp
Ala Gly Gln Thr
Ala Gly Thr Gln
Ala Asn Ala Thr
Ala Asn Asp Gly
Ala Asn Gly Asp
Ala Asn Thr Ala
Ala Gln Ala Ser
Ala Gln Gly Thr
Ala Gln Ser Ala
Ala Gln Thr Gly
Ala Ser Ala Gln
Ala Ser Gln Ala
Ala Thr Ala Asn
Ala Thr Gly Gln
Ala Thr Asn Ala
Ala Thr Gln Gly
Asp Ala Gly Asn
Asp Ala Asn Gly
Asp Gly Ala Asn
Asp Gly Gly Lys
Asp Gly Gly Gln
Asp Gly Lys Gly
Asp Gly Asn Ala
Asp Gly Gln Gly
Asp Lys Gly Gly
Asp Asn Ala Gly
Asp Asn Gly Ala
Asp Gln Gly Gly
Glu Gly Gly Asn
Glu Gly Asn Gly
Glu Asn Gly Gly
Gly Ala Asp Asn
Gly Ala Asn Asp
Gly Ala Gln Thr
Gly Ala Thr Gln
Gly Asp Ala Asn
Gly Asp Gly Lys
Gly Asp Gly Gln
Gly Asp Lys Gly
Gly Asp Asn Ala
Gly Asp Gln Gly
Gly Glu Gly Asn
Gly Glu Asn Gly
Gly Gly Asp Lys
Gly Gly Asp Gln
Gly Gly Glu Asn
Gly Gly Gly Trp
C17H21N5O5 (375.15426160000004)
Gly Gly Asn Glu
Gly Gly Gln Asp
Gly Gly Arg Ser
Gly Gly Ser Arg
Gly Gly Trp Gly
C17H21N5O5 (375.15426160000004)
Gly Lys Asp Gly
Gly Asn Ala Asp
Gly Asn Asp Ala
Gly Asn Glu Gly
Gly Asn Gly Glu
Gly Asn Ser Val
Gly Asn Val Ser
Gly Gln Ala Thr
Gly Gln Asp Gly
Gly Gln Gly Asp
Gly Gln Thr Ala
Gly Arg Gly Ser
Gly Arg Ser Gly
Gly Ser Gly Arg
Gly Ser Asn Val
Gly Ser Arg Gly
Gly Ser Val Asn
Gly Thr Ala Gln
Gly Thr Gln Ala
Gly Val Asn Ser
Gly Val Ser Asn
Gly Trp Gly Gly
C17H21N5O5 (375.15426160000004)
Lys Asp Gly Gly
Lys Gly Asp Gly
Asn Ala Ala Thr
Asn Ala Asp Gly
Asn Ala Gly Asp
Asn Ala Thr Ala
Asn Asp Ala Gly
Asn Asp Gly Ala
Asn Glu Gly Gly
Asn Gly Ala Asp
Asn Gly Asp Ala
Asn Gly Glu Gly
Asn Gly Gly Glu
Asn Gly Ser Val
Asn Gly Val Ser
Asn Ser Gly Val
Asn Ser Val Gly
Asn Thr Ala Ala
Asn Val Gly Ser
Asn Val Ser Gly
Gln Ala Ala Ser
Gln Ala Gly Thr
Gln Ala Ser Ala
Gln Ala Thr Gly
Gln Asp Gly Gly
Gln Gly Ala Thr
Gln Gly Asp Gly
Gln Gly Gly Asp
Gln Gly Thr Ala
Gln Ser Ala Ala
Gln Thr Ala Gly
Gln Thr Gly Ala
Arg Gly Gly Ser
Arg Gly Ser Gly
Arg Ser Gly Gly
Ser Ala Ala Gln
Ser Ala Gln Ala
Ser Gly Gly Arg
Ser Gly Asn Val
Ser Gly Arg Gly
Ser Gly Val Asn
Ser Asn Gly Val
Ser Asn Val Gly
Ser Gln Ala Ala
Ser Arg Gly Gly
Ser Val Gly Asn
Ser Val Asn Gly
Thr Ala Ala Asn
Thr Ala Gly Gln
Thr Ala Asn Ala
Thr Ala Gln Gly
Thr Gly Ala Gln
Thr Gly Gln Ala
Thr Asn Ala Ala
Thr Gln Ala Gly
Thr Gln Gly Ala
Val Gly Asn Ser
Val Gly Ser Asn
Val Asn Gly Ser
Val Asn Ser Gly
Val Ser Gly Asn
Val Ser Asn Gly
Trp Gly Gly Gly
C17H21N5O5 (375.15426160000004)
Simmondsin
N1,N1-dimethyl-4-[[4-(dimethylamino)phenyl](4-nitrophenyl)methyl]aniline
JWH 018 N-pentanoic acid metabolite-d4
C24H17D4NO3 (375.17724431199997)
propoxyphene hydrochloride
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
2-N,N-DIBENZYL SERINE BENZYL ESTER
C24H25NO3 (375.18343400000003)
benzyl 4-[3-(aminomethyl)azetidin-1-yl]piperidine-1-carboxylate,dihydrochloride
3-[2-(1-benzylpiperidin-4-yl)ethyl]-2,5-dihydropyrrolo[3,2-f][1,2]benzoxazol-6-one
Urea, N-[(2-chloro-6-ethoxy-3-quinolinyl)methyl]-N-cyclopentyl-N,N-dimethyl- (9CI)
C20H26ClN3O2 (375.17134460000005)
butyl prop-2-enoate,prop-2-enamide,prop-2-enoic acid,styrene
C21H29NO5 (375.20456240000004)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(4-methoxyphenyl)- (9CI)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(3-methoxyphenyl)- (9CI)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(2-methoxyphenyl)- (9CI)
Urea, N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]-N-(4-methoxyphenyl)- (9CI)
Urea, N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]-N-(3-methoxyphenyl)- (9CI)
Urea, N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]-N-(2-methoxyphenyl)- (9CI)
METHYL 9-[METHYL-4-(TRIFLUOROMETHOXY)ANILINO]-9-OXONONANOATE
C18H24F3NO4 (375.16573400000004)
tert-butyl 4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine-1-carboxylate
C16H20F3N3O4 (375.14058360000007)
Nalmefene hydrochloride
C21H26ClNO3 (375.16011160000005)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
D-PHENYLALANINE, BETA-PHENYL-N-[(PHENYLMETHOXY)CARBONYL]-
C23H21NO4 (375.14705060000006)
2-[[2-(4-HYDROXYPHENYL)ETHYL]AMINO]-1-[4-(PHENYLMETHOXY)PHENYL]-1-PROPANONE
C24H25NO3 (375.18343400000003)
4-methyl-N-(4-methylphenyl)-N-[4-(2-phenylethenyl)phenyl]aniline
Ciprofloxacin-D8 hydrochloride hydrate (see Data Sheet)
C17H11ClD8FN3O3 (375.160108024)
[5-[3-(1,3-dioxolan-2-yl)propyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
C19H26BNO6 (375.18530860000004)
Benzylmorphine
C24H25NO3 (375.18343400000003)
(2R)-2-(phenylmethoxycarbonylamino)-3-(4-phenylphenyl)propanoic acid
C23H21NO4 (375.14705060000006)
4-((4-(DIETHYLAMINO)-2-METHYLPHENYL)IMINO)-N-METHYL-1-OXO-1,4-DIHYDRONAPHTHALENE-2-CARBOXAMIDE
4-((4-(ETHYL(ISOPROPYL)AMINO)PHENYL)IMINO)-N-METHYL-1-OXO-1,4-DIHYDRONAPHTHALENE-2-CARBOXAMIDE
Tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate
1,4,7-Trihydroxy-3-(2-hydroxyethyl)-3,4,5-heptanetricarboxylic acid triammonium salt
2,2-IMinobis(N-(2,6-Dimethylphenyl)acetiamide Hydrochloride
C20H26ClN3O2 (375.17134460000005)
cis-(+/-)-2-[(N-Benzyl-N-methyl)aminomethyl]-1-(3-methoxyphenyl)cyclohexanol, Hydrochloride
4-Cyano-3,5-difluorophenyl 4-ethyl-[1,1-bi(cyclohexane)]-4-carboxylate
C22H27F2NO2 (375.20097460000005)
7-((S)-7-amino-5-azaspiro[2.4]heptan-5-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(TriMethyl)pentaMethylcyclopentadienylplatinuM(IV), 99\\%
Ethyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside
Methyl-5-hydroxy-1-methyl-6-oxo-2-[2-(phenylmethoxycarbonylamino) propan-2-yl]pyrimidin-4-carboxylate
C18H21N3O6 (375.14302860000004)
Pipethanate hydrochloride
C21H26ClNO3 (375.16011160000005)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent
2-Piperidineethanol, 1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propenyl]-, (E)-
3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine
11-[2-(4-Morpholinyl)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile
4-[(4-tert-butylphenyl)-oxomethyl]-N-[2-(2-pyridinyl)ethyl]-1H-pyrrole-2-carboxamide
(S)-cyano(3-phenoxyphenyl)methyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate
C24H25NO3 (375.18343400000003)
11-((3-morpholinopropyl)amino)-2,3-dihydro-1H-benzo[4,5]imidazo[1,2-a]cyclopenta[d]pyridine-4-carbonitrile
(2Z)-2-cyano-N-(4-ethoxyphenyl)-3-[3-methyl-4-(pyrrolidin-1-yl)phenyl]prop-2-enamide
1-(2-(4-Azidophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine
C19H20F3N5 (375.16707160000004)
1-(3-(1-(2-Morpholinoethyl)-1H-pyrazol-3-yl)biphenyl-3-yl)ethanone
(6,7-Difluoro-quinazolin-4-YL)-(1-methyl-2,2-diphenyl-ethyl)-amine
6-Ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-YL]pyrimidine-2,4-diamine
Theodrenaline
C17H21N5O5 (375.15426160000004)
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
(1R,2S,3S,4S,5S,8R,9R,12R)-5-hydroxy-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4,8-tricarboxylate
N-[2-(4-{[5-(aminomethyl)furan-3-yl]methoxy}phenyl)ethyl]-L-glutamine
1-cyclopropyl-6-fluoro-8-methoxy-7-[(3S)-3-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
C19H22FN3O4 (375.15942640000003)
(R)-gatifloxacin
C19H22FN3O4 (375.15942640000003)
The (R)-enantiomer of gatifloxacin.
[4-(2-Methoxyphenyl)-1-piperidinyl]-(5-methyl-1-phenyl-4-pyrazolyl)methanone
Glu-Asp-Ile
A tripeptide composed of L-glutamic acid, L-aspartic acid and L-isoleucine joined in sequence by peptide linkages.
4-[[4-(Dimethylamino)-7,7-dimethyl-6,8-dihydropyrimido[4,5-b][1,4]benzothiazin-9-yl]amino]butanoic acid
3-[(4-ethoxyphenoxy)methyl]-N-(3-pyridinylmethylene)benzohydrazide
N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N(2),N(2)-dimethylglycinamide
1-(4-methylphenyl)spiro[1,3-diazinane-5,4-2,3,3a,5-tetrahydro-1H-pyrrolo[1,2-a]quinoline]-2,4,6-trione
(2Z)-2-[2-hydroxy-3,4-dimethoxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexylidene]acetonitrile
(5Z)-5-[(E)-3-(4-dimethylaminophenyl)prop-2-enylidene]-1-(4-methylphenyl)-1,3-diazinane-2,4,6-trione
3,7-Dimethyl-1-(phenylmethyl)-8-[(phenylmethyl)amino]purine-2,6-dione
(9E)-12-(phosphonooxy)octadecenoate(3-)
C18H32O6P-3 (375.19364020000006)
(9Z)-12-(phosphonooxy)octadecenoate(3-)
C18H32O6P-3 (375.19364020000006)
1-(3,5-Dimethyl-1-pyrazolyl)-3-[2-(4-methoxyphenyl)-1-indolyl]-2-propanol
N-(4-ethoxyphenyl)-1,5-dimethyl-4-oxo-2-pyrrolo[3,2-c]quinolinecarboxamide
2-{2-[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methylene]hydrazino}-2-oxo-N-(2-pyridinylmethyl)acetamide
7,8-dimethyl-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-phenyl-3H-1,5-benzodiazepin-2-one
2-[[(5-Tert-butyl-2-methyl-3-furanyl)-oxomethyl]amino]-4,5-dimethoxybenzoic acid methyl ester
(2E)-3-(4-methoxyphenyl)-N-(11-oxo-6,8,9,11-tetrahydro-7H-pyrido[2,1-b]quinazolin-2-yl)acrylamide
N-cyclohexyl-3-methyl-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide
(1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate hydrochloride
N-[2-(dimethylamino)ethyl]-N-([1,3]dioxolo[4,5-f][1,3]benzothiazol-6-yl)cyclohexanecarboxamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
2-[(1R,3R,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3S,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3R,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R,4S)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
(1R,9S,10S,11S)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(2S,3R,4S)-3-[4-(3-cyanophenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]cyclobutanecarboxamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(methoxymethyl)-1-triazolyl]ethyl]-3-oxanyl]-4-pyridinecarboxamide
2-[(1S,3S,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3R,4aS,9aR)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3S,4aR,9aS)-6-[(2-cyclopropyl-1-oxoethyl)amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
N-[[(2S,3R,4R)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3S,4R)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2S,3S,4S)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3R,4R)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
N-[[(2R,3S,4S)-4-(hydroxymethyl)-3-phenyl-1-(2-pyridinylmethyl)-2-azetidinyl]methyl]-N-methylmethanesulfonamide
(1S,9R,10R,11R)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
6-{(E)-2-[4-(butan-2-yloxy)-3-ethoxyphenyl]ethenyl}-5-nitropyrimidine-2,4-diol
C18H21N3O6 (375.14302860000004)
Octyl 5-methyl-7-thiophen-2-yl-6,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
3-(3,4-dimethoxyphenyl)-N-[2-(1-hydroxy-3-methoxy-4-oxocyclohexa-2,5-dien-1-yl)ethyl]propanamide
Dibutyl 1-(N-trifluoroacetylamino)pentylphosphonate
C15H29F3NO4P (375.1786200000001)
Dibutyl 3-methyl-1-(N-trifluoroacetylamino)butylphosphonate
C15H29F3NO4P (375.1786200000001)
2-(2-Trimethylsilyloxyethoxy)-N-(2-(ethylaminoethyl)-4-quinolinecarboxamide
C19H29N3O3Si (375.19780840000004)
(2S)-2-[1-Oxo-4-(tetrahydro-2H-pyran-2-yloxy)butyl]pyrrolidine-1-carboxylic acid benzyl ester
C21H29NO5 (375.20456240000004)
(4-{4-[2-(gamma-L-glutamylamino)ethyl]phenoxymethyl}furan-2-yl)methanamine
A L-glutamine derivative obtained by formal condensation of the side-chain carboxy group of L-glutamine with one of the amino groups of 2-(4-{[5-(aminomethyl)furan-3-yl]methoxy}phenyl)ethan-1-amine.
Acetonitrile, ((2S,3R,4S,6R)-6-(beta-D-glucopyranosyloxy)-2-hydroxy-3,4-dimethoxycyclohexylidene)-, (2Z)-
(S)-gatifloxacin
C19H22FN3O4 (375.15942640000003)
The (S)-enantiomer of gatifloxacin.
FATP1-IN-1
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively[1].
Lixumistat (acetate)
C15H20F3N5O3 (375.1518166000001)
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model[1][2]. Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors[3].
NMDA-IN-1
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
(2s,3s)-2-{[(2s)-2-{[(2s)-2-amino-4-carboxy-1-hydroxybutylidene]amino}-3-carboxy-1-hydroxypropylidene]amino}-3-methylpentanoic acid
3,10-dihydroxy-3-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl)-5-oxa-1-azatricyclo[5.2.1.0⁴,¹⁰]decane-2,6-dione
(1r,4e,7r,17r)-4-ethylidene-7-methyl-6-methylidene-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-7-yl acetate
8-methyl-6-[(2-methylpropanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
C21H29NO5 (375.20456240000004)